BRAF Test
Mutations in the BRAF oncogene are common in a variety of cancers. BRAF mutations are found in 25-80%of melanomas, 30-80% of papillary thyroid cancer, 12-18% of colorectal cancers, and 8% of solid tumors overall.The BRAF Test offers critical information that guides oncologists in decisions regarding specific therapeuticoptions for patients.
Suggested for use in colorectal cancer patients who have tested negative for KRAS mutations
The BRAF Test is a highly sensitive and specific mutation analysis that guides oncologists as they seek to determine whether a patient will respond to drugs that target the Epidermal Growth Factor Receptor (EGFR). Recent studies suggest that patients who have BRAF mutations do not benefit from anti-EGFR monoclonal antibody therapy.
bioTheranostics BRAF test
- Identifies the V600E (1799T>A) mutation
- Accounts for more than 90% of all known and clinically relevant mutations
- In combination with KRAS mutation testing, can detect up to 50% of patients who will be non-responsive to the anti-EGFR therapies, cetuximab and panitumumab
+1 (877) 886-6739 client services
